Nektar Therapeutics

NKTR

Market cap $1.09B

Nektar Therapeutics (NKTR -2.34%) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January.

Shares of Nektar Therapeutics (NKTR 0.08%), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly enthusiastic about recently announced clinical trial results for its lead candidate, rezpegaldesleukin.

Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept.

Clinical-stage biotech Nektar Therapeutics (NKTR 15.06%) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such circumstances, investors flocked to the stock, and it closed the trading session a bit more than 15% higher.

Nektar Therapeutics Inc. NKTR on Thursday shared new data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology Congress.

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period Interim data presented for patients who received placebo during induction period and crossed over to receive 24 weeks of treatment with high dose rezpegaldesleukin show deepening of EASI-75 response to 62% and deepening of vIGA-AD 0/1 response to 38% SAN FRANCISCO , Sept. 18, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025.

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.

Nektar Therapeutics Inc. NKTR stock traded higher on Thursday, with a session volume of 2.80 million versus the average volume of 1.96 million, according to data from Benzinga Pro.